Skip to main content

Vertex Pharmaceutic(VRTX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low425.86
Day High434.07
Open:427.01
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Danaher (DHR) and Vertex Pharmaceuticals (VRTX)
Motley Fool
3 Healthcare Stocks With the Most Durable Competitive Moats
Motley Fool
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Innate Pharma (IPHA), Emergent Biosolutions (EBS)
Motley Fool
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
Motley Fool
Is Vertex Pharmaceuticals' Empire in Trouble?
Tipranks
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Vertex Pharmaceuticals (VRTX)
Tipranks
Morgan Stanley Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
StockStory
1 S&P 500 Stock on Our Watchlist and 2 Facing Challenges
TPR
Motley Fool
Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong.
Tipranks
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
Tipranks
Vertex Pharmaceuticals (VRTX) Receives a Buy from Morgan Stanley
Newswire.ca
Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells
Motley Fool
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?
Tipranks
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Green Thumb Industries (OtherGTBIF)
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)
StockStory
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds
VRTX
Tipranks
Vertex Advances FDA Filing for IgA Nephropathy Therapy
StockStory
1 Cash-Producing Stock with Promising Prospects and 2 We Turn Down
CALY
Motley Fool
Prediction: The Trump Bull Market Is About to End -- but These Stocks Will Rise Anyway
Motley Fool
2 Stocks I Plan to Hold for the Next 20 Years
Tipranks
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Vertex Pharmaceuticals (VRTX) and Sarepta Therapeutics (SRPT)
StockStory
2 Large-Cap Stocks with Exciting Potential and 1 Facing Headwinds
VRTX
Motley Fool
Where Will Vertex Pharmaceuticals Be in 1 Year?
Newswire.ca
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Motley Fool
CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now?
Motley Fool
Is CRISPR Therapeutics Stock a Buy Now?
Tipranks
RBC Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Motley Fool
My Top 3 Drug Stocks for March 2026
Motley Fool
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals
StockStory
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks
VRTX
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

Profile

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.